China Yingxia International, Inc.'s chairwoman and CEO is in talks with investor... ( HARBIN China March 6 Asia-FirstCa...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> NEWS

China Yingxia International, Inc.'s chairwoman and CEO is in talks with investors in China

Date:3/6/2009

HARBIN, China, March 6 /PRNewswire-Asia-FirstCall/ -- China Yingxia International, Inc. (OTC Bulletin Board: CYXI) ("China Yingxia" or "the Company"), a leading provider in the nutraceutical industry engaged in the development, manufacture and distribution of nutritional food products, dietary supplements and personal care products in the People's Republic of China ("PRC"), today disclosed that its CEO and chairwoman, Ms. Yingxia Jiao, is in talks with the committee formed by certain investors in China.

The investors with whom Ms. Jiao is in negotiations had loaned funds to her prior to the Company acquiring Harbin Yingxia Industrial Group Co., Ltd., our wholly-owned subsidiary in China. Currently, there are disputes between these investors and Ms. Jiao concerning interest payments on these loans. These disputes adversely affected the normal operations of Harbin Yingxia.

Ms. Jiao believes that the slowdown of the general economy in China contributed to the difficulties in cash flows of her businesses which have further affected the interest payments to the initial Chinese investors. The disputes that arose since November 2008 have caused our subsidiary, Harbin Yingxia Industrial Group Co., Ltd., to shut down its operations temporally on in late February 2009. As a result, the financial performance of the Company in the forth quarter of 2008 and the first quarter of 2009 have been and will continue to be adversely affected. The Company therefore withdraws its guidance of sales and net income for 2008 as well as other forward-looking statements previously set forth in SEC filings, press releases and other public discussions.

The Company expects to give a more detailed account of these matters, as well as the full financial implications, in a separate press release or in its annual report on Form 10-K for the fiscal year ended December 31, 2008. These difficulties may cause the Company to be un
'/>"/>

SOURCE China Yingxia International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine news :

1. China Healthcare Acquisition Corp. Announces Stockholder Approval of Charter Amendment to Permit Early Distribution of Its Trust Fund and to Permit Its Continued Existence Without Blank Check Company Provisions and Sets Payment Date
2. Chindex International, Inc. to Participate in the Piper Jaffray & ChinaVenture Investment Conference 2009
3. China Shenghuo Announces Management Expansion and Enhanced Internal Controls
4. China Sky One Medical Inc. Gets SFDA Approval for Calcium Folinate Injection
5. China Nepstar Chain Drugstore to Announce Fourth Quarter and Fiscal 2008 Financial Results on March 16
6. University of the Rockies Faculty and Students Travel to China to Share Western Philosophy
7. QSAI & SGS-CSTC to Begin Joint Food Analysis Services in China
8. China Sky One Medical, Inc. Exports Sumei Slim Patch to South Korea and Sudan
9. China Healthcare Acquisition Announces Record Date for Trust Fund Distribution
10. Hard To Treat Diseases (HTDS) Closes Acquisition of Mellow Hope, China
11. China YCT International Group, Inc. Announces Third Quarter Fiscal 2009 Results

Post Your Comments:

[0] Blood Thinner Combos Risky for Heart Attack Patients [0] Centegra Expands H1N1 Vaccines to General Public [0] Do Charitable Gift Donations Make a Difference?[0] China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 [0] Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security

Most Kidney Donors Lead Long, Healthy Lives NBTY Reports First Quarter Results Medical College of Wisconsin recognized for AIDS intervention research CCA Industries, Inc. Declares Dividend For The First Quarter Covance Reports Fourth Quarter and Full-Year 2008 Results Toxic Causation Training Day for Attorneys

Breaking Medicine Technology:Within3 Expands into Mobile Applications 2 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6 Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2 RecoverCare and MedaSTAT USA Complete Transaction 53601 1 RecoverCare and MedaSTAT USA Complete Transaction 53601 2 RecoverCare and MedaSTAT USA Complete Transaction 53601 3 BMP Sunstone Divests Ownership Stake in Alliance BMP Limited 53599 1 BMP Sunstone Divests Ownership Stake in Alliance BMP Limited 53599 2 AlphaRx and Venturepharm Announce Collaboration Agreement 53597 1 AlphaRx and Venturepharm Announce Collaboration Agreement 53597 2

[0] Within3 Expands into Mobile Applications [0] Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer [0] Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program

Other Medicine Technology:Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial 2 Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial 3 Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial 4 Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial 5 Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 2 Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 3 Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 4

Isotechnika Announces Interim Three Month Data from Phase 2b Kidney,Transplant Trial Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis

Medicine Products:

FlexNet™Spot Vital Signs 3800 Pulse Oximeter with TruTrak+ Technology 3775 Handheld Pulse Oximeter

China Yingxia International, Inc.'s chairwoman and CEO is in talks with investor...( HARBIN China March 6 Asia-FirstCa...),Health